Potent mast cell membrane stabilizer. Exhibits a wide range of anti-inflammatory effects. Inhibits antigen-induced release of cytokines, chemokines and proteases. Able to inhibit angiotensin II induced contractions (IC50 = 36 μM).
Store at +4°C. Store under desiccating conditions. The product can be stored for up to 12 months.
Soluble in DMSO to 100 mM
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use at an assay dependent concentration.
ab84833 staining Aryl hydrocarbon receptor in MDA-MB-231 cells treated with tranilast (ab120643), by ICC/IF. Increase in Aryl hydrocarbon receptor expression correlates with increased concentration of tranilast, as described in literature. The cells were incubated at 37°C for 24h in media containing different concentrations of ab120643 (telmisartan) in DMSO, fixed with 100% methanol for 5 minutes at -20°C and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab84833 (5 µg/ml) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 goat anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.
This product has been referenced in:
Shiota N et al. The anti-allergic compound tranilast attenuates inflammation and inhibits bone destruction in collagen-induced arthritis in mice. Br J Pharmacol159:626-35 (2010).
Read more (PubMed: 20067475) »
Jin D et al. Tranilast, an anti-allergic drug, possesses antagonistic potency to angiotensin II. Eur J Pharmacol361:199-205 (1998).
Read more (PubMed: 9865509) »
Hishikawa K et al. Tranilast restores cytokine-induced nitric oxide production against platelet-derived growth factor in vascular smooth muscle cells. J Cardiovasc Pharmacol28:200-7 (1996).
Read more (PubMed: 8856474) »